LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 46 filers reported holding LYRA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,178,994 | -5.1% | 301,533 | -0.2% | 0.00% | 0.0% |
| Q2 2023 | $1,242,186 | +98.6% | 302,235 | 0.0% | 0.00% | +200.0% |
| Q1 2023 | $625,626 | -34.1% | 302,235 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $949,018 | +199.4% | 302,235 | +378.1% | 0.00% | +100.0% |
| Q3 2022 | $317,000 | -0.3% | 63,210 | +12.4% | 0.00% | 0.0% |
| Q2 2022 | $318,000 | +102.5% | 56,229 | +43.6% | 0.00% | – |
| Q1 2022 | $157,000 | -8.2% | 39,167 | 0.0% | 0.00% | – |
| Q4 2021 | $171,000 | -52.2% | 39,167 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $358,000 | +14.0% | 39,167 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $314,000 | -30.8% | 39,167 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $454,000 | +1.6% | 39,167 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $447,000 | +2.1% | 39,167 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $438,000 | +157.6% | 39,167 | +161.1% | 0.00% | – |
| Q2 2020 | $170,000 | – | 15,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 1,100,852 | $12,550,000 | 16.38% |
| Soleus Capital Management, L.P. | 456,138 | $5,199,000 | 0.69% |
| Ikarian Capital, LLC | 815,364 | $9,295,000 | 0.41% |
| Perceptive Advisors | 3,222,561 | $36,737,000 | 0.39% |
| Affinity Asset Advisors, LLC | 50,000 | $570,000 | 0.30% |
| RA Capital Management | 815,849 | $9,301,000 | 0.13% |
| ArrowMark Colorado Holdings LLC | 775,888 | $8,845,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 87,353 | $996,000 | 0.04% |
| Altium Capital Management LP | 5,218 | $59,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 49,000 | $559,000 | 0.01% |